id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-323601-qzruawe1	Dufranc, Etienne	IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome	2020-04-22		.txt	text/plain	903	62	43	Because some patients may develop refractory or relapsing HLH, alternative treatments targeting specific immune pathways or cytokine signaling have been tested [1] . Tocilizumab, a monoclonal antibody targeting the receptor of IL6, fully reverses the multi-organ failure and the cytokine profile of the CAR-T cell-induced cytokinerelease syndrome [3] . In the herein study, we reviewed the outcomes of nine critically ill patients who received tocilizumab to treat HLH ( Table 1 ). In critically ill patients with severe forms of HLH, etoposide rapidly reverses cytokine storm and improves clinical condition [1] . Alternatives should thus be discussed in adult patients with chemotherapy-induced bone marrow failure, underlying autoimmune diseases requiring cytotoxic agents, or with a moderate form of HLH not related to hematological malignancies. In conclusion, IL-6-R blockade with tocilizumab may be an alternative in critically ill patients with moderate forms of HLH.	./cache/cord-323601-qzruawe1.txt	./txt/cord-323601-qzruawe1.txt